000 | 01425 a2200409 4500 | ||
---|---|---|---|
005 | 20250517212304.0 | ||
264 | 0 | _c20190218 | |
008 | 201902s 0 0 eng d | ||
022 | _a1534-6080 | ||
024 | 7 |
_a10.1097/TP.0000000000002247 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aVille, Simon | |
245 | 0 | 0 |
_aBelatacept and Autoimmune Adverse Events. _h[electronic resource] |
260 |
_bTransplantation _c07 2018 |
||
300 |
_ae355-e356 p. _bdigital |
||
500 | _aPublication Type: Case Reports; Letter | ||
650 | 0 | 4 |
_aAbatacept _xadverse effects |
650 | 0 | 4 | _aAdministration, Cutaneous |
650 | 0 | 4 | _aAdult |
650 | 0 | 4 |
_aAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis _xcomplications |
650 | 0 | 4 |
_aAutoimmunity _xdrug effects |
650 | 0 | 4 | _aBiopsy |
650 | 0 | 4 |
_aCalcitriol _xanalogs & derivatives |
650 | 0 | 4 |
_aGraft Rejection _xpathology |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aImmunosuppressive Agents _xadverse effects |
650 | 0 | 4 |
_aKidney Failure, Chronic _xetiology |
650 | 0 | 4 |
_aKidney Transplantation _xadverse effects |
650 | 0 | 4 | _aMale |
650 | 0 | 4 |
_aPsoriasis _xdrug therapy |
650 | 0 | 4 |
_aRituximab _xtherapeutic use |
650 | 0 | 4 |
_aSkin _ximmunology |
650 | 0 | 4 | _aTreatment Outcome |
700 | 1 | _aCantarovich, Diego | |
773 | 0 |
_tTransplantation _gvol. 102 _gno. 7 _gp. e355-e356 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1097/TP.0000000000002247 _zAvailable from publisher's website |
999 |
_c28304075 _d28304075 |